As India has approved two vaccines for emergency use the country might soon get a nasal vaccine against Coronavirus as well, as the trails are all set to begin in Nagpur soon.
As per updates, Bharat Biotech is planning to start phase 1 and 2 trials of the nasal vaccine at Gillurkar Multi Speciality in Nagpur.
Bharat Biotech’s head Dr Krishna Ella informed that they are working on a nasal vaccine and have partnered with the Washington University School of Medicine. Research has proven that the nasal vaccine is the best choice. Coronavirus also attacks through the nose.
Dr Chandrashekar Gillurkar said that “We are all set to host the trials for the nasal Covaxin in the next two weeks. Enough scientific evidence is available that vaccines given through nasal route are more effective than injected ones. Bharat Biotech is in the process to submit a proposal to the DCGI shortly”.
The trials will be conducted on at least 30-45 healthy volunteers above the age of 18 till the age of 65 years at four trial sites in the country – Bhuvneshwar, Pune, Nagpur, and Hyderabad.
Bharat Biotech is working on two intranasal vaccines one with US-based vaccine maker FluGen and scientists from the University of Wisconsin Madison and the other with the University of Washington School of Medicine.
